Phaseline

Companies › EpicentRx

EpicentRx: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AdAPT-001
Oncolytic virus
–Phase 2Solid Tumor, AdultDec 2026
RRx-001
unclear - likely prodrug or small molecule with cytoprotective properties
–Phase 2Oral MucositisJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04673942AdAPT-001Phase 2Solid Tumor, AdultOncologyDec 2026
NCT05966194RRx-001Phase 2Oral MucositisOncologyJul 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Elpiscience (Suzhou) Biopharma Ryvu Therapeutics Criterium Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Inhibrx Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.